Literature DB >> 10496654

Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin.

A Gysler1, B Kleuser, W Sippl, K Lange, H C Korting, H D Höltje, H C Korting.   

Abstract

PURPOSE: To investigate pharmacokinetic differences between the nonhalogenated double ester prednicarbate (PC) and the fluorinated monoester betamethasone 17-valerate (BM17V) their metabolism in human keratinocytes and fibroblasts as well as their permeation and biotransformation in reconstructed epidermis and excised human skin was compared. Special attention was given to the 17-monoesters because of their high receptor affinity and antiproliferative effects.
METHODS: Glucocorticoid penetration was determined using Franz diffusion cells, quantifying metabolite concentrations by HPLC. Chemical stability and reactivity of the monoesters was determined by molecular modeling analysis.
RESULTS: PC accumulated in the stratum corneum. A considerable amount of penetrating PC was hydrolyzed by viable keratinocytes to prednisolone 17-ethylcarbonate (PI7EC), P17EC permeated the skin very rapidly when compared to BM17V. Overall P17EC concentrations in viable tissue were low. Inside of the acceptor fluid, but not within the tissue, P17EC was converted to the more stable prednisolone 21-ethylcarbonate (P21EC).
CONCLUSIONS: The inactivation of highly potent, but also cell toxic, 17-monoesters to almost inactive 21-congeners seen with isolated cell monolayers appears less important in the skin. In vitro determination of the dermal 17-monoesters concentrations may allow the prediction of the atrophogenic risk in man. BM17V levels exceeding P17EC concentration about 6-fold may contribute to its lower tolerance when compared to PC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10496654     DOI: 10.1023/a:1018946924585

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  application of the human dermal model skin(2) ZK 1350 to phototoxicity and skin corrosivity testing.

Authors:  M Liebsch; B Döring; T A Donelly; P Logemann; L A Rheins; H Spielmann
Journal:  Toxicol In Vitro       Date:  1995-08       Impact factor: 3.500

2.  0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.

Authors:  H C Korting; D Vieluf; M Kerscher
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Surfactant-induced dermatitis: comparison of corneosurfametry with predictive testing on human and reconstructed skin.

Authors:  G E Piérard; V Goffin; T Hermanns-Lê; J E Arrese; C Piérard-Franchimont
Journal:  J Am Acad Dermatol       Date:  1995-09       Impact factor: 11.527

4.  Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts.

Authors:  A Gysler; K Lange; H C Korting; M Schäfer-Korting
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

5.  In vivo correlation between stratum corneum reservoir function and percutaneous absorption.

Authors:  A Rougier; D Dupuis; C Lotte; R Roguet; H Schaefer
Journal:  J Invest Dermatol       Date:  1983-09       Impact factor: 8.551

6.  Glucocorticoid receptors in human synovial tissue and relative receptor affinities of glucocorticoid-21-esters.

Authors:  M Pörtner; H Möllmann; P Rohdewald
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

7.  Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids.

Authors:  M Schäfer-Korting; H C Korting; M J Kerscher; S Lenhard
Journal:  Clin Pharmacol Ther       Date:  1993-10       Impact factor: 6.875

8.  Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness.

Authors:  J Lévy; J Gassmüller; G Schröder; H Audring; N Sönnichsen
Journal:  Skin Pharmacol       Date:  1994

9.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

10.  Maintenance of skin viability during in vitro percutaneous absorption/metabolism studies.

Authors:  S W Collier; N M Sheikh; A Sakr; J L Lichtin; R F Stewart; R L Bronaugh
Journal:  Toxicol Appl Pharmacol       Date:  1989-07       Impact factor: 4.219

View more
  5 in total

Review 1.  Xenobiotica-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models.

Authors:  F Oesch; E Fabian; Robert Landsiedel
Journal:  Arch Toxicol       Date:  2018-06-18       Impact factor: 5.153

Review 2.  Xenobiotic-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models.

Authors:  F Oesch; E Fabian; K Guth; R Landsiedel
Journal:  Arch Toxicol       Date:  2014-11-05       Impact factor: 5.153

3.  Phimosis and topical steroids: new clinical findings.

Authors:  Nicola Zampieri; Michele Corroppolo; Veronica Zuin; Sanzio Bianchi; Francesco Saverio Camoglio
Journal:  Pediatr Surg Int       Date:  2007-02-17       Impact factor: 1.827

4.  In Vitro Modeling of Skin Barrier Disruption and its Recovery by Ceramide-Based Formulations.

Authors:  Barbora Amélie Čuříková-Kindlová; Aneta Vovesná; Anna Nováčková; Jarmila Zbytovská
Journal:  AAPS PharmSciTech       Date:  2021-12-14       Impact factor: 3.246

5.  Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake.

Authors:  Jana Stecová; Wolfgang Mehnert; Tobias Blaschke; Burkhard Kleuser; Ramadurai Sivaramakrishnan; Christos C Zouboulis; Holger Seltmann; Hans Christian Korting; Klaus D Kramer; Monika Schäfer-Korting
Journal:  Pharm Res       Date:  2007-03-20       Impact factor: 4.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.